logo-loader
MaxCyte

MaxCyte's latest deal 'a perfect relationship' says CEO Doug Doerfler

MaxCyte Inc (LON:MXCT) chief executive Doug Doerfler tells Proactive: ''This is the second relationship we have inked using our CARMA platform''.

CARMA retrains the cells found in blood to attack cancer.

The AIM-listed life sciences group is teaming up with Washington University in St Louis and will use CARMA to develop immunotherapy drug candidates.

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £70.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read